PE20040911A1 - Derivados de 3h-quinazolin-4-ona como inhibidores selectivos de la monoaminooxidasa b - Google Patents
Derivados de 3h-quinazolin-4-ona como inhibidores selectivos de la monoaminooxidasa bInfo
- Publication number
- PE20040911A1 PE20040911A1 PE2003001256A PE2003001256A PE20040911A1 PE 20040911 A1 PE20040911 A1 PE 20040911A1 PE 2003001256 A PE2003001256 A PE 2003001256A PE 2003001256 A PE2003001256 A PE 2003001256A PE 20040911 A1 PE20040911 A1 PE 20040911A1
- Authority
- PE
- Peru
- Prior art keywords
- quinazolin
- alkyl
- ona
- compounds
- fluor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE 3H-QUINAZOLIN-4-ONA DE FORMULA I, INCLUYENDO SUS SALES FARMACEUTICAMENTE ACEPTABLES, EN DONDE R1 ES (CH2)n-CO-NR5R6, (CH2)n-COOR7, (CH2)n-NR5R6, ENTRE OTROS; R2 ES H, HALOGENO o ALQUILO C1-C6; R3 ES H, ALQUILO C1-C6, CICLOALQUILO C3-C6, ENTRE OTROS; R4 ES HALOGENO, FLUORALQUILO C1-C6, CN, ALCOXI C1-C6, ENTRE OTROS; R5 Y R6 SON, H o ALQUILO C1-C6; R7 ES H o ALQUILO C1-C6; m ES 1, 2 o 3; n ES 0, 1 o 2. SON COMPUESTOS PREFERIDOS: 2-[7-(3-FLUOR-BENCILOXI)-4-OXO-4H-QUINAZOLIN-3-IL]-ACETAMIDA; 2-[7-(3-FLUOR-BENCILOXI)-4-OXO-4H-QUINAZOLIN-3-IL]-PROPIONAMIDA; 2-[7-(4-FLUOR-BENCILOXI)-4-OXO-4H-QUINAZOLIN-3-IL]-ACETAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCESO PARA LA OBTENCION DE DICHOS COMPUESTOS Y A UN MEDICAMENTO. DICHOS COMPUESTOS SON UTILES PARA EL TRATAMIENTO Y/O PREVENCION DE ENFERMADES MEDIADAS POR INHIBIDORES DE LA MONOAMINA-OXIDASA B COMO SON LA ENFERMEDAD DE ALZHEIMER O LA DEMENCIA SENIL
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02027700 | 2002-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20040911A1 true PE20040911A1 (es) | 2004-12-11 |
Family
ID=32524001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003001256A PE20040911A1 (es) | 2002-12-13 | 2003-12-10 | Derivados de 3h-quinazolin-4-ona como inhibidores selectivos de la monoaminooxidasa b |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7087612B2 (es) |
| EP (1) | EP1572666B1 (es) |
| JP (1) | JP4384053B2 (es) |
| KR (1) | KR100707532B1 (es) |
| CN (1) | CN100418954C (es) |
| AR (1) | AR042362A1 (es) |
| AT (1) | ATE335729T1 (es) |
| AU (1) | AU2003293798B8 (es) |
| BR (1) | BR0317282A (es) |
| CA (1) | CA2509633A1 (es) |
| CL (1) | CL2003002565A1 (es) |
| DE (1) | DE60307512T2 (es) |
| ES (1) | ES2270154T3 (es) |
| GT (1) | GT200300284A (es) |
| MX (1) | MXPA05006124A (es) |
| MY (1) | MY141743A (es) |
| PA (1) | PA8591901A1 (es) |
| PE (1) | PE20040911A1 (es) |
| PL (1) | PL377474A1 (es) |
| RU (1) | RU2340604C2 (es) |
| TW (1) | TW200424180A (es) |
| UY (1) | UY28120A1 (es) |
| WO (1) | WO2004054985A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1838296B1 (en) | 2004-10-20 | 2012-08-08 | Resverlogix Corp. | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases |
| JP2008531509A (ja) | 2005-02-25 | 2008-08-14 | エフ．ホフマン−ラ ロシュ アーゲー | 医薬品成分の改良された分散性を有する錠剤 |
| US8410109B2 (en) | 2005-07-29 | 2013-04-02 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| GB0525068D0 (en) * | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| JP4876690B2 (ja) * | 2006-04-21 | 2012-02-15 | 三菱瓦斯化学株式会社 | キナゾリン−４−オン誘導体の製造法 |
| WO2008087736A1 (ja) * | 2007-01-19 | 2008-07-24 | Ube Industries, Ltd. | アラルキルオキシ又はヘテロアラルキルオキシ基を有する芳香族アミンの製法 |
| AU2007345526B2 (en) | 2007-02-01 | 2013-02-28 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular diseases |
| WO2009158404A1 (en) | 2008-06-26 | 2009-12-30 | Resverlogix Corp. | Methods of preparing quinazolinone derivatives |
| NZ594332A (en) | 2009-01-08 | 2013-09-27 | Resverlogix Corp | Compounds for the prevention and treatment of cardiovascular disease |
| KR101709492B1 (ko) | 2009-03-18 | 2017-02-23 | 리스버로직스 코퍼레이션 | 신규한 소염제 |
| ES2706651T3 (es) | 2009-04-22 | 2019-03-29 | Resverlogix Corp | Nuevos agentes antiinflamatorios |
| SI2773354T1 (sl) | 2011-11-01 | 2019-08-30 | Resverlogix Corp. | Peroralne formulacije s takojšnjim sproščanjem za substituirane kinazolinone |
| WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
| WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
| KR20150096794A (ko) | 2012-12-21 | 2015-08-25 | 제니쓰 에피제네틱스 코포레이션 | 브로모도메인 저해제로서의 신규한 헤테로사이클릭 화합물 |
| KR102662814B1 (ko) | 2015-03-13 | 2024-05-03 | 리스버로직스 코퍼레이션 | 보체 관련 질환을 치료하기 위한 조성물 및 치료 방법 |
| CN106146410B (zh) * | 2015-04-03 | 2018-10-12 | 中南大学 | 6-氨基-4(3h)-喹唑啉酮衍生物及其合成方法和用途 |
| CN108191667B (zh) * | 2018-01-04 | 2021-03-26 | 利尔化学股份有限公司 | 2-硝基-4-三氟甲基苯甲酸甲酯的制备方法 |
| CN109553534A (zh) * | 2018-11-27 | 2019-04-02 | 常州大学 | 一种2-硝基-4-甲氧基苯甲酸的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6136273A (ja) * | 1984-07-26 | 1986-02-20 | Mitsubishi Yuka Yakuhin Kk | ２−フエニルアルキル−４（３ｈ）−キナゾリノン誘導体 |
| NZ304291A (en) * | 1995-03-14 | 1999-01-28 | Novartis Ag | Trisubstituted phenyl derivatives, preparation and pharmaceutical compositions thereof |
| IL117659A (en) * | 1995-04-13 | 2000-12-06 | Dainippon Pharmaceutical Co | Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same |
| US5679715A (en) | 1995-06-07 | 1997-10-21 | Harris; Richard Y. | Method for treating multiple sclerosis |
| US5783577A (en) * | 1995-09-15 | 1998-07-21 | Trega Biosciences, Inc. | Synthesis of quinazolinone libraries and derivatives thereof |
| WO1997033572A1 (en) | 1996-03-15 | 1997-09-18 | Somerset Pharmaceuticals, Inc. | Method for preventing and treating peripheral neurophathy by administering selegiline |
| US6294532B1 (en) * | 1997-08-22 | 2001-09-25 | Zeneca Limited | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
| US6890930B1 (en) * | 1999-09-28 | 2005-05-10 | 3-Dimensional Pharmaceuticals, Inc. | Quinazolinones |
| AU1359801A (en) | 1999-11-05 | 2001-06-06 | Vela Pharmaceuticals Inc. | Methods and compositions for treating reward deficiency syndrome |
-
2003
- 2003-12-08 JP JP2004559781A patent/JP4384053B2/ja not_active Expired - Lifetime
- 2003-12-08 KR KR1020057010696A patent/KR100707532B1/ko not_active Expired - Fee Related
- 2003-12-08 PL PL377474A patent/PL377474A1/pl not_active Application Discontinuation
- 2003-12-08 MX MXPA05006124A patent/MXPA05006124A/es active IP Right Grant
- 2003-12-08 EP EP03789170A patent/EP1572666B1/en not_active Expired - Lifetime
- 2003-12-08 CN CNB2003801052982A patent/CN100418954C/zh not_active Expired - Fee Related
- 2003-12-08 AU AU2003293798A patent/AU2003293798B8/en not_active Ceased
- 2003-12-08 AT AT03789170T patent/ATE335729T1/de not_active IP Right Cessation
- 2003-12-08 RU RU2005121908/04A patent/RU2340604C2/ru not_active IP Right Cessation
- 2003-12-08 CA CA002509633A patent/CA2509633A1/en not_active Abandoned
- 2003-12-08 WO PCT/EP2003/013888 patent/WO2004054985A1/en not_active Ceased
- 2003-12-08 DE DE60307512T patent/DE60307512T2/de not_active Expired - Lifetime
- 2003-12-08 BR BR0317282-1A patent/BR0317282A/pt not_active IP Right Cessation
- 2003-12-08 ES ES03789170T patent/ES2270154T3/es not_active Expired - Lifetime
- 2003-12-09 TW TW092134699A patent/TW200424180A/zh unknown
- 2003-12-10 CL CL200302565A patent/CL2003002565A1/es unknown
- 2003-12-10 PE PE2003001256A patent/PE20040911A1/es not_active Application Discontinuation
- 2003-12-10 PA PA20038591901A patent/PA8591901A1/es unknown
- 2003-12-11 AR ARP030104562A patent/AR042362A1/es unknown
- 2003-12-11 GT GT200300284A patent/GT200300284A/es unknown
- 2003-12-11 UY UY28120A patent/UY28120A1/es not_active Application Discontinuation
- 2003-12-12 MY MYPI20034764A patent/MY141743A/en unknown
- 2003-12-13 US US10/734,949 patent/US7087612B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006513177A (ja) | 2006-04-20 |
| AU2003293798A1 (en) | 2004-07-09 |
| UY28120A1 (es) | 2004-06-30 |
| DE60307512T2 (de) | 2007-02-08 |
| EP1572666A1 (en) | 2005-09-14 |
| KR100707532B1 (ko) | 2007-04-12 |
| CN100418954C (zh) | 2008-09-17 |
| AU2003293798B8 (en) | 2009-02-12 |
| US7087612B2 (en) | 2006-08-08 |
| AR042362A1 (es) | 2005-06-15 |
| AU2003293798B2 (en) | 2009-01-15 |
| CN1720237A (zh) | 2006-01-11 |
| PA8591901A1 (es) | 2004-11-26 |
| TW200424180A (en) | 2004-11-16 |
| KR20050085587A (ko) | 2005-08-29 |
| GT200300284A (es) | 2004-07-14 |
| BR0317282A (pt) | 2005-11-08 |
| US20040142951A1 (en) | 2004-07-22 |
| WO2004054985A1 (en) | 2004-07-01 |
| ES2270154T3 (es) | 2007-04-01 |
| MY141743A (en) | 2010-06-30 |
| PL377474A1 (pl) | 2006-02-06 |
| EP1572666B1 (en) | 2006-08-09 |
| CA2509633A1 (en) | 2004-07-01 |
| JP4384053B2 (ja) | 2009-12-16 |
| RU2005121908A (ru) | 2006-01-27 |
| RU2340604C2 (ru) | 2008-12-10 |
| MXPA05006124A (es) | 2005-08-16 |
| ATE335729T1 (de) | 2006-09-15 |
| CL2003002565A1 (es) | 2005-01-07 |
| DE60307512D1 (de) | 2006-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20040911A1 (es) | Derivados de 3h-quinazolin-4-ona como inhibidores selectivos de la monoaminooxidasa b | |
| AR036103A1 (es) | Imidazotriazinas, procedimiento para su preparacion, uso de dichos compuestos para la manufactura de un medicamento para enfermedades neurodegenerativas y dicho medicamento | |
| UY26782A1 (es) | Derivados del benzotiazol | |
| CO5700824A2 (es) | Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| DE602005016261D1 (de) | Substituierte arylaminderivate und verwendungsverfahren | |
| DE602004024900D1 (de) | Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren | |
| ATE404552T1 (de) | Substituierte isochinolinderivate und anwendungsverfahren | |
| ATE349435T1 (de) | Dpiv-inhibitoren auf glutaminbasis | |
| ATE545413T1 (de) | Antagonisten des opioidrezeptors | |
| ATE361288T1 (de) | N-(3,-dimethylindolin-6-yl)ä2-ä(4- | |
| NO20051871L (no) | Opioidreseptorantagonister | |
| ATE411985T1 (de) | Substituierte piperazine als modulatoren des melanocortinrezeptors | |
| IS2293B (is) | Arýl sambrædd asapólýsýklísk efnasambönd | |
| AR040489A1 (es) | Compuestos derivados de 3-fenil-propionamido, 3-fenil-acrilamido y 3-fenil-propinamido, su uso para la elaboracion de medicamentos, un proceso para elaborar los compuestos y medicamentos que los contienen | |
| CY1106645T1 (el) | Παραγωγα 1,2,4 τριαμινοβενζολης χρησιμα για τη θεραπευτικη αντιμετωπιση διαταραχων του κεντρικου νευρικου συστηματος | |
| AR040278A1 (es) | Ligandos del receptor de glucocorticoides para el tratamiento de trastornos metabolicos | |
| PE20050141A1 (es) | DERIVADOS DE 2-ALQUINIL-Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIDINA COMO ANTAGONISTAS DEL RECEPTOR A2a ADENOSINA | |
| UY27842A1 (es) | Fluorobenzamidas | |
| GT200000197A (es) | 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6- morfolin-4-il-4-o tolil-piridin-3-il)-isobutiramida. | |
| PE20040594A1 (es) | Derivados de isoquinolina | |
| NO20064951L (no) | 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse | |
| NO20064982L (no) | 1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav | |
| PE20060630A1 (es) | Amidas sustituidas de acido tienopirrolcarboxilico, amidas del acido pirrolotiazolcarboxilico y analogos relacionados como inhibidores de la caseina cinasa ie | |
| AR051686A1 (es) | Derivados de piridotienopirimidina; composiciones farmaceuticas que los contienen y su empleo en la fabricacion de un medicamento para el tratamiento de enfermedaes mediadas por inhibicion de pde4. | |
| NO20062599L (no) | Fremgangsmate for syntese av perindopril og farmasoytisk akseptable salter derav |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |